Cargando…

Methylome Variation Predicts Exemestane Resistance in Advanced ER(+) Breast Cancer

BACKGROUND: More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond to hormone therapy eventually acquire resistance. Although the mechanisms of hormone therapy resistance remain unclear, aberrant DNA methylation has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiao-ran, Zhang, Ru-yan, Gong, Hao, Rugo, Hope S., Chen, Ling-bo, Fu, Yuan, Che, Jian-wei, Tie, Jian, Shao, Bin, Wan, Feng-ling, Kong, Wei-yao, Song, Guo-hong, Jiang, Han-fang, Xu, Guo-bing, Li, Hui-ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057408/ https://www.ncbi.nlm.nih.gov/pubmed/32129154 http://dx.doi.org/10.1177/1533033819896331

Ejemplares similares

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer
por: Yang, Juan‐Cheng, et al.
Publicado: (2019)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2013)

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial
por: Guerrieri-Gonzaga, Aliana, et al.
Publicado: (2021)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis
por: Xu, Liang, et al.
Publicado: (2022)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2014)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

A review of the use of exemestane in early breast cancer
por: Robinson, Andrew
Publicado: (2009)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

Exemestane/palbociclib/prednisolone: Various toxicities: case report
Publicado: (2020)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout
por: Tseng, Chia-Chun, et al.
Publicado: (2020)

Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment
por: Amaral, Cristina, et al.
Publicado: (2012)

Long-term efficacy and safety of exemestane in the treatment of breast cancer
por: Walker, GA, et al.
Publicado: (2013)

Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics
por: Kumar, Abhinesh, et al.
Publicado: (2013)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10
por: Wang, Ya-Hui, et al.
Publicado: (2017)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives
por: Peterson, Amity, et al.
Publicado: (2017)

The effect of genotype and in utero environment on interindividual variation in neonate DNA methylomes
por: Teh, Ai Ling, et al.
Publicado: (2014)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
por: Aktas, Bilge, et al.
Publicado: (2016)

Development and evaluation of exemestane-loaded lyotropic liquid crystalline gel formulations
por: Musa, Muhammad Nuh, et al.
Publicado: (2017)

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

Methotrexate-Lactoferrin Targeted Exemestane Cubosomes for Synergistic Breast Cancer Therapy
por: Mokhtar, Sarah, et al.
Publicado: (2022)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

Methylome and Transcriptome-Based Integration Analysis Identified Molecular Signatures Associated With Meningitis Induced by Glaesserella parasuis
por: Guo, Ling, et al.
Publicado: (2022)

Transcriptome, Methylome and Genomic Variations Analysis of Ectopic Thyroid Glands
por: Abu-Khudir, Rasha, et al.
Publicado: (2010)

Variation of DNA Methylome of Zebrafish Cells under Cold Pressure
por: Han, Bingshe, et al.
Publicado: (2016)

Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype
por: Chen, Xiao-Qiong, et al.
Publicado: (2020)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_059eo30kk3mlk750kv24arfd2c